BRVE (BRVE) Stock Price & Analysis
BRVE (BRVE) rose 1.79% to USD 26.74 as of September 8, 2026 at 12:48 UTC, according to Nexqual real-time market data.
BRVE last closed at USD 26.74; the session ranged USD 25.39–27.48 on volume of 272,081 shares. Market capitalization is —, with a 52-week range of USD 24.31–32 (NGM). Source: Nexqual, September 8, 2026 at 12:48 UTC.
Key Statistics (as of September 8, 2026 at 12:48 UTC)
| Price | USD 26.74 |
|---|---|
| Change | ▲ 1.79% (up) |
| Previous Close | USD 26.74 |
| Open | USD 26.74 |
| Day Range | USD 25.39 – 27.48 |
| 52-Week Range | USD 24.31 – 32 |
| Volume | 272,081 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (BRVE)
Nexqual's technical model rates BRVE "SELL" based on 0 bullish and 2 bearish signals across 22 daily candles, as of September 8, 2026 at 12:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.37 (neutral) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SCTX | Scribe Therapeutics Inc. | USD 28.67 | ▼ 7.22% |
| COAG | Hemab Therapeutics Holdings, In | USD 44.41 | ▼ 0.65% |
| LTGO | Latigo Biotherapeutics, Inc. | USD 23.04 | ▲ 5.83% |
| BLSM | BlossomHill Therapeutics, Inc. | USD 22.01 | ▲ 13.57% |
| KLRA | Kailera Therapeutics, Inc. | USD 16.23 | ▲ 2.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:48 UTC. This page is informational and not investment advice.